Juno believes that a patient’s own immune system can be activated to recognize disease – that the potential power to fight certain diseases lies within each of us. We are developing investigational treatments that seek to help the body’s immune system find and fight certain cancers.
The CAR T cell therapies that Juno is investigating are not approved by the FDA. This means that their safety and efficacy are still being studied in clinical trials. For participants in these trials, each investigational drug is created specifically for the patient, using the individual’s own T cells.
During this first step, the patient’s lymphocytes (white blood cells) are collected at a clinic or infusion center. The lymphocytes are separated from the rest of the patient’s blood cells and plasma in a process called apheresis.
The patient’s lymphocytes are immediately packaged and delivered to JuMP, Juno’s manufacturing facility.
Once the lymphocytes arrive at JuMP, the cells are genetically reengineered with the goal of recognizing and killing cancer cells.
In many cases, the patient receives conditioning chemotherapy while waiting for T cell therapy.
Juno ships the investigational therapy to the patient’s health care team. The patient then receives CAR T cell therapy and is carefully monitored for any signs of adverse reaactions.
The decision whether to participate in a clinical trial is a very personal one. Your healthcare team will help guide you through this decision and provide you with information about the risks and benefits of trial participation.
Our pipeline, or work in progress, includes a number of treatments at various stages of research. These include non-Hodgkin lymphoma (NHL), pediatric acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL).
These therapies have not been approved by FDA. This means that their safety and efficacy are still being studied in clinical trials.
Acute Lymphoblastic Leukemia (ALL) is an uncontrolled proliferation of lymphoblasts, which are immature white blood cells. The lymphoblasts, which are produced in the bone marrow, cause damage and death by inhibiting the production of normal cells. Approximately 6,000 patients are diagnosed with ALL in the United States each year, and although just over half of the new diagnoses are in adult patients, the vast majority of the approximately 1,400 deaths per year occur in adults. There are two main types of ALL, B cell ALL and T cell ALL. Approximately 80% of cases of ALL are B cell ALL, which we aim to address with our CD19 product candidates. (Adapted from American Cancer Society, Cancer A – Z.)
Every year about 13,000 people are diagnosed with AML in the United States, with the incidence increasing in the advanced age group. AML is often incurable with standard systemic therapy. Despite the many advances in the field of hematopoietic cell transplant (HCT), relapse after transplantation continues to be a major problem, particularly in patients entering HCT with high risk/poor prognosis diseases. (Adapted from American Cancer Society, Cancer A – Z.)
Chronic lymphocytic leukemia (CLL) is a common kind of blood cancer that occurs when the bone marrow makes too many lymphocytes, or white blood cells. About one quarter of new leukemia cases are classified as CLL. It is a slow-growing disease that mostly affects older adults. According to the American Cancer Society, more than 20,000 people will be diagnosed with CLL in 2017. (Adapted from American Cancer Society, Cancer A – Z.)
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United State. It mostly occurs in people in the their 60s. It typically starts as a mass in a lymph node, such as the chest, abdomen, neck or armpit. (Adapted from American Cancer Society, Cancer A – Z.)
Lung cancer is the second most common cancer in men and women (after skin cancer) and is typically diagnosed at an advanced stage. Most lung cancer diagnoses are related to smoking or exposure to environmental factors but some occur in people with no known risk factors. Recommended treatments vary depending on the type of lung cancer and the stage of the disease. (Adapted from American Cancer Society, Cancer A – Z.)
Mesothelioma is a rare and aggressive type of cancer that grows in the lining of the lungs or abdomen, or in the lining around the heart cavity. It most typically is found in the lungs. The most common risk factor for mesothelioma is exposure to asbestos. Often, the disease is not diagnosed until it has advanced and affected many organs. At this time there is no cure for mesothelioma. (Adapted from American Cancer Society, Cancer A – Z.)
Multiple myeloma is a form of blood cancer that occurs when white blood cells known as plasma cells, which are typically found in the bone marrow, grow out of control and develop into tumors. Approximately 30,000 new cases of multiple myeloma will be diagnosed this year in the U.S. There are few known risk factors for developing this disease and it may not cause signs or symptoms that would lead to a diagnosis until it has advanced to the kidneys and other organs. (Adapted from American Cancer Society, Cancer A – Z.)
Neuroblastoma is a type of cancer that starts in the early nerve cells, known as neuroblasts, of infants and young children under the age of 10. It accounts for approximately 6 percent of all cancers in children, with about 700 new cases in the U.S. each year. In infants, it is the most common solid cancer. (Adapted from American Cancer Society, Cancer A – Z.)
Non-Hodgkin lymphoma (NHL) is not a single disease, but rather a group of several closely related cancers with different patterns of treatment. Over 70,000 cases of NHL are diagnosed in the U.S. each year. NHL is typically divided into aggressive (fast-growing) and indolent (slow-growing) subtypes. Juno is planning to evaluate multiple product candidates in Phase 1 trials for common types of relapsed or refractory (R/R) B cell NHL of both aggressive and indolent subtypes. (Adapted from American Cancer Society, Cancer A – Z.)
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for up to 85% of all lung cancer diagnoses in the U.S. Within NSCLC, there are many subtypes of the disease depending on the different types of lung cells. Immunotherapy for NSCLC is a newer type of treatment that boosts a person’s immune system to help fight their cancer. (Adapted from American Cancer Society, Cancer A – Z.)
Ovarian cancer mainly affects women over the age of 63, with more than 22,000 diagnoses in the U.S. this year. While all women are at risk of developing ovarian cancer, those with the BRCA2 gene mutation are at increased risk for developing this type of cancer. Treatment depends on the type of cancer and the stage of the disease. (Adapted from American Cancer Society, Cancer A – Z.)
Breast cancer is the second most common cancer in American women, with more than 250,000 new cases diagnosed this year. In triple-negative breast cancer, the breast cancer cells test negative for the hormones estrogen (ER-) and progesterone (PR-) and the protein HER2 (HER2-). As a result, this type of cancer does not respond to hormonal therapy or therapies that target HER2. Approximately 10-20% of breast cancers fall into this category and are more common in young women and those who are African-American or Hispanic/Latina. (Adapted from American Cancer Society, Cancer A – Z.)
This is a partial list of the leading cancer advocacy organizations, and are generally considered highly reliable sources of information and patient support.
*Celgene does not endorse any of these organizations or their communications.